Fredun Pharmaceuticals Ltd has allotted 2,71,200 equity shares after 10 investors exercised conversion rights on 90,400 warrants. A previous 1:2 bonus issue adjusted each outstanding warrant to three equity shares. The conversion expands Fredun's equity base, making the resulting dilution and its effect on per-share metrics the key points for existing shareholders to track.
Fredun Pharmaceuticals Allots 2.71 Lakh Shares on Warrant Conversion
2,71,200 new equity shares of ₹10 face value each have been allotted.
90,400 warrants were exercised by 10 investors after bonus-adjusted conversion terms.
Reader Takeaway: Warrant conversion brings remaining consideration into the company, while the larger equity base creates shareholder dilution.
What just happened
Fredun Pharmaceuticals Ltd completed the allotment of 2,71,200 equity shares following the conversion of 90,400 warrants held by 10 investors.
The warrants were originally allotted on December 29, 2025. Fredun subsequently undertook a 1:2 bonus issue, requiring the warrant conversion entitlement to be adjusted in accordance with applicable SEBI regulations.
Following that adjustment, each outstanding warrant became exercisable into three equity shares. The warrant holders paid the balance consideration required for conversion, allowing the company to issue the new shares.
The allotted shares carry a face value of ₹10 each and will rank pari passu with Fredun Pharmaceuticals' existing equity shares.
Why this matters
The immediate consequence is an increase in Fredun Pharmaceuticals' equity base. Existing shareholders therefore need to account for the additional 2,71,200 shares when assessing future per-share financial metrics.
A larger number of outstanding shares can dilute earnings per share if profits do not increase proportionately. The filing does not provide an estimate of the resulting EPS impact, so any numerical dilution assumption would be premature.
The conversion itself is different from a fresh warrant placement. These warrants had already been allotted in December 2025, and the current event represents exercise of the existing conversion rights after payment of the balance consideration.
What changes now
Ten investors received shares through the conversion. They include Alchemy Capital Management Pvt Ltd, Alchemy Long Term Ventures Fund (Series 2), Ajay Kumar Aggarwal, Divya Aggarwal, Swati Goel, Sweta Chokhany, Vartika Chokhany, Vivek Dhir, Ceramet Consultants Private Limited and Nav Ratan Bhaiya.
Because the bonus adjustment changed the conversion ratio, 90,400 exercised warrants resulted in 2,71,200 equity shares, exactly three shares for each warrant converted.
Risks to watch
Dilution is the main shareholder consideration arising directly from the filing. Investors should watch whether the expanded share count is matched by growth in earnings over subsequent reporting periods.
The filing states that all warrant holders paid the balance consideration. Investors can therefore track the company's subsequent disclosures for the updated paid-up equity capital and the effect of the enlarged share base on future EPS.
What to track next
The next useful checkpoints are Fredun Pharmaceuticals' revised equity structure, future quarterly earnings per share and any further outstanding convertible securities that could expand the share count again.